KLSE (MYR): GENTING (3182)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
4.64
Today's Change
-0.09 (1.90%)
Day's Change
4.64 - 4.73
Trading Volume
3,420,000
2024-08-01
2024-08-01
2024-07-25
2024-07-24
2024-07-22
AngTayKor
1,899 posts
Posted by AngTayKor > 2022-06-02 12:52 | Report Abuse
Posted by SinGor > 1 hour ago | Report Abuse
TauRx is promising but very small trial sample. Need another 7--10years to get FDA approval even large
scale Trial was done yesterday......Better hope Covid is Gone and Customers return to Betting
----------------------------------------------------
This is the only phase 3 trial which can see significant slowdown in decline for a disease modifying AD drug. Nobody has done it before and nobody is able to do it for the next 10 years. The smaller the trial population, the harder it is to show statistical significance. Hence those iffy drugs done by large pharmas will try to do very large patient size trial to improve the statistical significance score. Before we do the clinical trial design, we already have an estimated drug performance benchmark using knowledge from previous clinical trials. Then need to show it in a new clinical trial by powering it with the number of trial patients using computer simulated graphs. Our earlier computer simulation estimated abt 400 patients is sufficient to show strong statistical significance figure due to the extremely powerful drug effect of HMTM. To be safe, increase the patient population by 25% to 500 patients.
Further cost cutting measures such reducing the number of trial centres by half can yield significant cost savings and allowed us to increase the patient population to almost 600 patients.